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Dear Editor,
Please find enclosed our manuscript entitled "Repression of RNA polymerase III in 
Saccharomyces cerevisiae is correlated with degradation of its largest subunit, C160” which 
we would like to be considered for publication in BBA Gene Regulatory Mechanisms. 
Previous studies have shown a role of ubiquitylation and proteasomal degradation in control 
of the largest catalytical subunits of both, RNA polymerase I and II. We feel that so far 
undescribed degradation of the largest subunit of RNA polymerase III is of general interest 
and our results will be relevant. 
Thank you very much for your efforts.
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Magdalena Boguta  
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Abstract 
Respiratory growth and various stress conditions repress RNA polymerase III (Pol III) 
transcription in Saccharomyces cerevisiae. Here we report a correlation between Pol III 
transcription repression and degradation of the largest Pol III catalytic subunit, C160. We 
observed C160 degradation in response to transfer of yeast from fermentation to respiration 
conditions, as well as treatment with rapamycin or inhibition of nucleotide biosynthesis. We 
also detected a ubiquitylated form of C160 and demonstrated that C160 protein degradation is 
dependent on proteasome activity. A comparable study of changes in C160 levels and C160 
association with chromatin suggested that modification of C160 that promotes its degradation 
is not required to release Pol III from tDNA upon transfer of yeast from glucose to respiratory 
growth conditions. However, the steady state levels of other Pol III subunits besides C160 are 
also decreased upon this transfer, but the stability of the Pol III complex increased. The results 
indicate that Pol III repression activates degradation of C160 to reduce the amount of existing 
Pol III complex and prevent its de novo assembly. 
Introduction 
RNA synthesis in the eukaryote nucleus is carried out by the multisubunit RNA 
polymerases I, II, and III. Whereas Pol I and Pol II synthesize ribosomal and mainly 
messenger RNA, respectively, Pol III transcribes small RNAs, including transfer RNAs, 5S 
ribosomal RNA, and U6 small nuclear RNA. Yeast Saccharomyces cerevisiae Pol III 
comprises 17 subunits. The Pol III core, composed of ten subunits, is conserved relative to Pol 
I and Pol II. The largest catalytic Pol III subunit, C160, shows substantial homology to the 
largest subunits of Pol I and Pol II, A190 and Rpb1, respectively. Rbp1 contains a repetitive 
carboxyl terminal domain (CTD), unique to Pol II which, depending on its phosphorylation 
state, controls subsequent steps of transcription and processing of the primary transcript [1]. 
Specific features of a carboxyl-terminal extension of C160 that are specific for Pol III were 
revealed by structure analysis [2] but relevant functional studies are lacking for this subunit. 
Over two decades ago Rbp1 was identified as a target for ubiquitylation-mediated degradation 
in response to DNA damage [3,4]. Blockage of transcription due to DNA damage promotes 
2Rbp1 ubiquitylation in the nucleus and its proteasomal degradation is associated with gene 
transcription [5,6]. Ubiquitylation of Rpb1 is reversible in that once DNA damage is repaired, 
the ubiquitin moiety is removed by the ubiquitin protease Ubp3, which in turn stabilizes Pol II 
[7]. Pol II proteolysis is an evolutionarily conserved, tightly regulated, multistep pathway [8]. 
The S. cerevisiae Rsp5 protein was the first ubiquitin ligase implicated in Rpb1 degradation 
and is the only essential HECT family ubiquitin ligase in budding yeast [9]. Pol II 
ubiquitylation is signed by phosphorylation of CTD, the site of Rsp5 association [10–12]. 
NEDD4, the mammalian homologue of Rsp5, was also shown to bind to and ubiquitylate Pol 
II [13]. In addition, polyubiquitylation of Rbp1 for proteasomal degradation requires the 
Elc1–Cul3 ubiquitin ligase complex that acts in tandem with Rsp5 [14]. Degradation of Rpb1 
in the presence of DNA damage requires the Cdc48 protein, a component of the ubiquitin-
proteasome system that interacts with the chromatin remodeling complex INO80 that can 
disrupt contacts between ubiquitylated Rpb1 and chromatin [15]. Although originally 
identified as a response to DNA damage, Rpb1 degradation also occurs under a number of 
conditions that lead to Pol II stalling/arrest during transcript elongation [8]. There are at least 
two alternative pathways that regulate Rpb1 degradation and depend on the stress type. In 
response to rapamycin, which induces stress similar to that associated with nutrient limitation, 
chromatin-bound Rpb1 is degraded by a ubiquitin-independent mechanism involving the Rrd1 
peptidyl prolyl isomerase [16]. 
Expression of the largest Pol I subunit, A190, both in yeast and mammals, is also 
controlled by ubiquitylation and proteasomal degradation [17,18]. In yeast, A190 
ubiquitylation serves as a checkpoint for a cold-sensitive step during rRNA transcription. The 
A190 protein is stabilized via Ubp10-mediated deubiquitylation that is required to achieve 
optimal levels of ribosomes and cell growth [17]. In contrast to Rpb1, DNA damage and 
rapamycin treatment has no effect on A190 levels [17,19], indicating that Pol I degradation 
has a different regulation pathway than does Pol II.
We are interested in mechanisms that control Pol III biogenesis and activity. Pol III is 
specialized to carry out high-level transcription of short DNA templates and, like Pol I, is 
regulated in a global manner. Previous studies explored mechanisms that account for 
repression of Pol III-mediated transcription (referred by [20]). In negative regulation of Pol III 
transcription in yeast, the Maf1 protein mediates various stress signals to Pol III [21,22]. 
Under stress conditions, Maf1 directly binds the Pol III complex, which then dissociates from 
chromatin [23]. Pol III levels are also down-regulated by TOR signaling via phosphorylation 
of the Pol III subunit C53 [24]. 
Here we report a decrease in steady state levels of the largest subunit of Pol III, C160, 
under various conditions that repress Pol III gene transcription. We discovered that the C160 
protein is also ubiquitylated and degraded by proteasomes, similar to the largest subunits of 
Pol I and Pol II. Moreover, we analyzed C160 degradation in the context of association of Pol 
III with chromatin and stability of the Pol III complex. 
Material and Methods
Growth conditions
3Yeast were grown in: rich media YPD (2% glucose, 2% peptone, 1% yeast extract), or 
YPGly (2% glycerol, 2% peptone, 1% yeast extract) or minimal media SC-ura or SC-trp, (2% 
glucose, 0.67% yeast nitrogen base, supplemented with 20 μg/ml of the amino acids required 
for growth, except for uracil or tryptophan, respectively). 200 μg/ml geneticin, 200 ng/ml 
rapamycin (RAP) or 100 µg/ml cycloheximide (CHX) were added to YPD, as required. For 
nucleotide depletion strains grown on SC-ura with 100 µg/ml mycophenolic acid (MPA) or 
100 µg/ml 6-azauracil (6-AU). For testing proteasomal degradation YPGly medium was 
supplemented with 50 µM MG132 or equal amount of dissolvent – DMSO. Sporulation 
medium contained 0.05% glucose, 0.1% yeast extract and 1% potassium acetate. Solid media 
contained 2% agar. All reagents used for media were Difco products.
Yeast strains and plasmids
The yeast strains used in this study are listed in Supplementary Table 1. For testing 
C160 stability upon nucleotide depletion, MW4415 strain was transformed with empty uracil 
plasmid – pFL44L [25]. Overexpression of His-tagged ubiquitin was performed from 6His-
Ub (ampR/TRP1) plasmid [26].
For tagging C160 with TAP or HA in different strains, appropriate sequence was 
amplified by PCR, using as a template the genomic DNA of MB159-4D derivative encoding 
C160-TAP or MW4415 strain encoding C160-HA and specific C160TAPF (5’-
GGACGCTGTTGAAGGTGTTT-3’) and C160TAPR (5’-AAACGTTGACGCGAGTTTTT-
3’) primers. Transformants were selected on SC-ura for C160-TAP or on YPD medium 
supplemented with geneticin for C160-HA. In every case, the addition of tag sequence was 
confirmed by PCR and by western blot method with PAP (Sigma-Aldrich) or HA (Covance) 
antibody.
The EM4-3C strain was obtained by genetic cross of W303 C160-HA and FA212/10-
2D. Deletion of RRD1 was confirmed by PCR with RRD1-338 (5’-
TGAGTCTCGTTCGCCTCTTT-3’) and RRD1_307 (5’-TACCAGGCCCCTTCTCTTG-3’) 
primers. Presence of C160-HA was confirmed by PCR using C160TAPF and C160TAPR 
primers, and by western blotting with HA-specific antibody.
The YPH499 C160-TAP ump1Δ strain was obtained by transformation of ump1Δ 
deletion with TRP1 cassette amplified by PCR, using as a template the genomic DNA of 
YAS6 strain and primers UMP1_A (5’-CATGTGATGTGACTAGTGTTTGTGA-3’) and 
UMP1_D (5’-TGGGCTGAGAAGTTGAGTATATAGG-3’). Transformants were selected on 
SC-trp and replacement of UMP1 locus by TRP1 deletion cassette was confirmed by PCR.
Protein extraction and western blot analysis
The protein extraction was described earlier [27]. Protein extracts were separated on 
SDS-PAGE using an acrylamide : bisacrylamide ratio of 37:5:1, for detection of Maf1 
phosphorylation the modified acrylamide : bisacrylamide ratio (33.5:0.3) was used. After 
electrophoresis proteins were transferred to nitrocellulose membrane (Milipore). The 
membrane was blocked in TBST (10 mM Tris, 150 mM NaCl, 0.05% Tween 20) containing 
45% fat-free dry milk for 30 min and then incubated with appropriate antibody: mouse 
monoclonal antibodies anti-HA (Covance) at a 1:5000 dilution for o/n at 4 °C, anti-GFP 
(Roche) at a 1:5000 dilution for 1 h, anti-Ubiquitine (ENZO) at a 1:1000 dilution for o/n at 4 
°C, anti-Vma2 (Molecular Probes) at a 1:10000 dilution for 1 h, anti-Pgk1 (Abcam) at a 
1:20000 dilution for 1 h and anti-Actin (Merck-Millipore) at a 1:2000 dilution for 1 h, rabbit 
polyclonal antibodies anti-HA (Sigma) at a 1:2000 dilution for 1 h, anti-C82 at a 1:5000 
dilution for o/n at 4 °C, anti-C53 at a 1:20000 dilution for o/n at 4 °C, anti-AC40 (Gramsh) at 
a 1:1000 dilution for o/n at 4 °C and anti-Maf1 at a 1:10000 dilution for o/n at 4 °C. 
Antibodies specific for Pol III subunits (except AC40) and Maf1 specific antibody were a gift 
from O. Lefebvre. Blots with TAP-tagged proteins were incubated with anti-PAP antibody at 
a 1:3000 dilution for 1h. PAP is peroxidase anti-peroxidase antibody with no need of 
secondary antibody. Than membrane was incubated with secondary antibody at a dilution of 
1:5000 for 1 h. Secondary anti-mouse or anti-rabbit antibody was coupled to horseradish 
peroxidase (DAKO). The signal on the membrane was visualized by chemiluminescence 
using the ECL detection kit (Bio-Rad).
Immunoprecipitation of C160-HA
Yeast cells expressing HA epitope-tagged C160 (MW4415) were grown in YPD 
medium to exponential phase, than shifted to pre-warmed YPGly medium and incubated for 
30 min at 37 °C. From both conditions, pellets, corresponding to 100 ml of culture, were 
resuspended in 0.5 ml IP buffer (50 mM HEPES-KOH [pH 7.5], 100 mM NaCl, 1 mM 
EDTA, 0.05% NP-40, 0.5 mM DTT, 5% glycerol, O-Complete protease inhibitor [Roche]). 
Lysis was performed in the presence of glass beads using a Vibramax disruptor (GENE) at 
maximum speed for 1 h at 4 °C, than beads were washed with 0,3 ml IP buffer. The cell 
debris were eliminated by centrifugation (20 min at 4°C and 14000 rpm). The protein 
concentration was determined with the Bio-Rad protein assay. 100 µl of a suspension of 
Dynabeads PanMouse IgG magnetic beads (Invitrogen), washed three times with 0.5% bovine 
serum albumin in phosphate-buffered saline (PBS), was incubated with mouse monoclonal 
anti-HA antibody (6 µg) for 3.5 h at 4 °C. After washing in 0.5% bovine serum albumin in 
PBS (two times) and then in IP buffer (two times), the beads were incubated overnight with 4 
mg of protein extracts in IP buffer with gentle shaking at 4 °C. Then beads were washed three 
times with IP buffer. Protocol is based on [28]. Immunoprecipitated proteins were released 
from the beads by boiling them for 5 min and separated by 6% SDS-PAGE and analyzed by 
western blotting with anti-HA antibody.
Tandem purification of C160-TAP and His-Ub
Yeast cells expressing TAP epitope-tagged C160 and transformed with 6His-Ub 
plasmid were grown in SC-trp medium at 30 °C. Expression of tagged ubiquitin was induced 
by CuSO4 addition to final concentration 100 µM, then cells were grown for 4 h to 
exponential phase. 1.6 l of culture was harvested, washed with cold water and stored at 
-80°C for further analyzes. Pellet was resuspended in 10 ml TMN150 buffer (50 mM Tris-
HCl [pH 7.8], 150 mM NaCl, 0,1% NP-40, 1.5 mM MgCl2, 5 mM β-mercaptoethanol) with 
2x concentrated O-Complete protease inhibitor (Roche). Lysis was performed in the presence 
5of zircon beads using a Vortex (GENE) in 5 cycles (1 min of disruption, 1 min incubation on 
ice). The cell debris were eliminated by centrifugation (30 min at 4 °C and 14000 rpm). 
Protein extract was incubated with 1 ml IgG Sepharose (SIGMA), washed two times with 5 
ml TMN150 buffer and once with 2 ml TMN150 buffer with O-complete for 2 h in 4 °C with 
rotation. After washing two times with 10 ml TMN1000 buffer (the same as TMN150 but 
with 1M NaCl) and two times with 5 ml TMN150 buffer, purified proteins were eluted in 
denaturing conditions two times with 300 µl Ni-WBI buffer (50 mM Tris-HCl [pH 7.8], 300 
mM NaCl, 0,1% NP-40, 10 mM imidazole, 1.5 mM MgCl2, 6 M guanidinium chloride, 5 mM 
β-mercaptoethanol) for 10 min in RT with rotation. Protein eluate was added to 200 µl Ni-
NTA agarose, washed two times with 1 ml TMN150 buffer, and incubated 3 h in in 4 °C with 
rotation. Then Ni-NTA Agarose (Sigma) was washed ones with 1 ml Ni-WBI buffer and two 
times with 1 ml Ni-WBII buffer (50 mM Tris-HCl [pH 7.8], 50 mM NaCl, 0,1% NP-40, 10 
mM imidazole, 5 mM β-mercaptoethanol), proteins were eluted with 300 µl Ni-EB buffer (the 
same as Ni-WBII, but with 150 mM imidazole) for 5 min in RT with rotation. Eluted proteins 
were precipitated o/n at -20 °C with 1.5 ml acetone and 1 µl glycoblue, then resuspended in 
30 µl 2x SB buffer and boiled 5 min in 98 °C. Proteins were separated by 6% SDS-PAGE and 
analyzed by western blotting with anti-PAP and anti-Ub antibodies.
AC40-GFP and C160-HA co-immunoprecipitation
Yeast cells expressing HA epitope-tagged C160 and AC40-GFP or expressing only 
HA epitope-tagged C160 (MW4415) were grown in YPD medium to exponential phase, than 
shifted to pre-warmed YPGly medium and incubated for 2 hours at 37 °C. 
Co-immunoprecipitation was performed as described for C160 in [28] except that 0.5 mg of 
protein extract was used to immunoprecipitation.
Chromatin immunoprecipitation (ChIP)
Yeast cells expressing HA epitope-tagged C160 (MW4415) were grown in YPD 
medium to exponential phase, than shifted to pre-warmed YPGly medium and incubated for 2 
hours at 37 °C, from both conditions 17 OD600 units of cells were collected. Yeast chromatin 
isolation and sonication were prepared as described previously [23]. The preparation of 
magnetic beads, immunoprecipitation (anti-HA), elution from beads, decrosslinking and DNA 
purification were done as described previously [29]. For ChIP experiment, the input and 
immunoprecipitated samples were assayed by quantitative PCR to assess the extent of protein 
occupancy at different genomic regions. The sequence of primers used are available upon 
request. PCR reactions contained 2 μl of DNA template, 300 nM primer pairs and 5 μl of 
2×SYBR Green reaction mix (ABO). Quantitative PCR was performed on Roche LightCycler 
480 using a 5 min soak at 95 °C, followed by 45 cycles of 15 s at 95 °C, 15 s at 55 °C and 20 
s at 72 °C (with a plate read after each cycle). A melting curve analysis was performed for 
each sample after PCR amplification to ensure that a single product of expected melting curve 
characteristics was obtained. Occupancy values (in arbitrary units) were calculated by 
determining the apparent immunoprecipitation efficiency (the amount of PCR product in the 
immunoprecipitated sample divided by the amount of PCR product in the input sample).
6Results
C160 subunit has limited stability that varies depending on Pol III transcription activity
To evaluate C160 protein stability, yeast cells encoding C160 tagged with the HA epitope 
were treated with cycloheximide (CHX) in a time-course experiment, and cell lysates were 
analyzed by immunoblotting. The blots were probed with anti-HA antibodies followed by 
antibodies directed against other Pol III subunits and the Pol III repressor, Maf1. The level of 
actin was used to normalize sample loading. The blot showed that incubation with CHX for 
120 min resulted in continuing C160 degradation as evidenced by a decrease in C160 levels of  
relative to untreated cells (Fig. 1A). Meanwhile the levels of Pol III-specific subunits C82 and 
C53 appeared to be also reduced. After 30 min of CHX treatment, Maf1 was 
dephosphorylated likely due to stress excreted by CHX, but Maf1 protein levels were not 
affected as the incubation time increased. This observation is consistent with a mode of Maf1 
control by phosphorylation rather than expression levels [30].
Reduced steady state levels of C160 protein were previously detected in the rpc128-1007 
mutant that shows defective Pol III complex assembly [28]. Quantification of the blots 
showed that incubation of wild type cells with CHX for 120 min resulted in a decrease in 
C160 levels of about 50% relative to untreated cells (Fig. 1B). In the CHX assay, C160 
stability in rpc128-1007 cells was indeed lower relative to the control strain (Fig. 1B). Since 
Rpb1 levels are not affected in rpc128-1007 cells [28], we suspected that this specific 
degradation of C160 is a consequence of inefficient Pol III-mediated transcription. 
Levels of C160 protein decline under stress conditions that repress Pol III transcription 
To further explore the correlation between the decrease in C160 levels and Pol III activity, we 
examined the effect of various conditions known to repress Pol III transcriptional activity. 
First we used rapamycin, which induces transcriptional effects similar to those seen for 
nutrient limitation and inhibits Pol III transcription genome-wide [31]. Treatment of wild type 
cells with rapamycin down-regulated C160 levels by 80% after two hours. However, these 
C160 levels were higher than that seen in rapamycin-treated rrd1∆ mutant cells that are 
deficient in peptidylprolyl isomerase, which may play a role in C160 degradation (Fig. 2A). 
Perhaps, in response to rapamycin treatment, the same mechanism used to degrade excess Pol 
II and Pol III may be induced. 
Transcription elongation in vivo can be inhibited by 6-azauracil (6-AU), which blocks UTP 
synthesis and also reduces cellular pools of GTP [32] and mycophenolic acid (MPA) that in 
turn impairs de novo guanosine nucleotide synthesis [33]. Although all RNA polymerases 
require nucleotides as substrates for RNA synthesis, the effect of nucleotide-depleting drugs is 
especially pronounced for Pol I and Pol III [34]. In contrast, mRNA synthesis driven by Pol II 
is only slightly decreased by MPA and 6-AU treatment, with the exception of some transcripts 
involved in nucleotide biosynthesis that show specific up-regulation [35,36]. Since 6-AU 
treatment significantly down-regulates tRNA synthesis [34], we assessed how it affects C160 
7levels. Yeast cells encoding C160-HA were collected at different time points after 6-AU or 
MPA addition and examined by western blotting with HA-specific antibody (Fig. 2B). 
Analysis of equal amounts of crude extracts showed a nearly two-fold decline in C160 levels 
after inhibition of nucleotide synthesis for one hour, and this decline presumably reflected 
C160 degradation. 
Previously we showed a sharp decrease in the levels of newly synthesized Pol III transcripts 
during transition of yeast from fermentative to glycerol-based medium followed by incubation 
at elevated temperature [37,38]. Based on these results we examined the effect of this 
transition on C160 expression. Cells encoding C160-HA fusion that were grown in glucose 
medium under optimal conditions (YPD) were transferred to medium containing glycerol 
(YPGly) and incubated at 37 °C. Western blot analysis of samples taken every 30 min showed 
a continuous decrease of C160 levels to about 40% of initial values within 120 min (Fig. 2C). 
Notably, transition of yeast from fermentative to glycerol-based growth resulted in decreased 
levels of C160 proteins fused to various tags and in strains having different genetic 
backgrounds (Fig. S1). Taken together, these results show that diverse conditions that repress 
Pol III-mediated transcription lead also to a down-regulation of the largest Pol III subunit, 
C160. 
The switch between fermentation and respiration results in proteasomal degradation of 
C160 
The decrease in C160 protein levels under conditions that cause Pol III repression suggested 
that C160 expression could be controlled by the ubiquitin proteasome system. Ubiquitylation 
of yeast C160 protein has been detected in three independent proteome-wide screens [39–41], 
but has not been validated by molecular studies. 
To identify ubiquitylated C160 forms, HA-tagged C160 was immuno-purified from yeast 
grown first in glucose medium and then shifted to medium containing glycerol with 
incubation at 37 °C for 30 min (Fig. 3A). Analysis of immuno-purified fractions by western 
blotting with HA-specific antibody identified additional bands that migrated slower than the 
predicted 170 kDa C160-HA protein, suggestive of C160 ubiquitylation (Fig. 3A). 
To examine C160 ubiquitylation, a two-step purification involving TAP-tagged C160 and 
His-tagged ubiquitin was performed. Incubation of crude cell extracts with IgG Sepharose that 
can bind the TAP epitope resulted in a near complete depletion of C160 from the supernatant 
(Fig. 3B, left panel). The immuno-purified C160-TAP was then incubated with nickel resin 
following by western blot analysis of the eluted fraction with TAP- and ubiquitin (Ub)-
specific antibodies. Both assays identified a single band migrating above 170 kDa (Fig. 3B, 
right panel) that was predicted to correspond to the ubiquitylated form of C160-TAP. 
To determine if C160 levels were post-translationally regulated by a proteasome-mediated 
degradation pathway, we assessed the effects of the proteasome inhibitor MG132 on C160 
protein levels. Because wild-type yeast contain transport proteins that actively pump MG132 
out of cells, we analyzed cells lacking the major drug transporters Pdr5 and Snq2. Yeast were 
grown in glucose medium and transferred to medium with glycerol followed by a 2 h 
incubation at 37 °C. Treatment of cells grown in glycerol medium with the proteasome 
8inhibitor MG132 showed increased endogenous C160 protein levels (Fig. 4A, left panel), 
supporting proteasome-dependent degradation of C160. Moreover, inactivation of the gene 
encoding the Ump1 protein that is required for 20S proteasome maturation also resulted in 
increased C160 levels (Fig. 4A right panel).
Ubiquitylation and degradation of the Pol II Rbp1 subunit induced by DNA damage is 
dependent on the Rsp5 ubiquitin ligase [9,14]. Rpb1 degradation was not observed in 
temperature-sensitive rsp5-1 that carries a mutation in the HECT domain of Rsp5 that directly 
affects its catalytic activity, even when a DNA-damaging reagent was applied at elevated 
temperatures [42]. Here we examined whether Rsp5 might similarly be involved in 
ubiquitylation and degradation of C160 upon transfer of yeast to medium with glycerol 
following 2 h incubation at 37 °C. We used rsp5-1 and another temperature-sensitive mutant, 
rsp5-19, harboring a substitution in the WW3 domain that governs the interaction of Rsp5 
with its substrates [43]. The rsp5 mutants showed no difference in C160 protein degradation 
in medium with a non-fermentable carbon source (Fig. 4B) suggesting that mechanisms that 
regulate C160 ubiquitiylation and degradation differ from those for Rpb1. The levels and 
phosphorylation status of C53, another Pol III subunit, and Maf1 regulatory protein were also 
unaffected by rsp5 alleles (Fig. 4B). 
C160 loss is related to dissociation of Pol III from tDNA and enhancement of 
interactions between Pol III complex subunits
The switch between fermentation and aerobic respiration induced by growth on non-
fermentable carbon sources causes widespread changes in gene transcription, including 
repression of tDNA transcription [37]. Transfer of cells from glucose medium (YPD) to 
medium with glycerol (YPGly) followed by a 2 h incubation at 37 °C corresponded to a 
marked decrease in Pol III activity due to strong repression mediated by Maf1 [37]. A 
significant decrease in levels of primary transcripts of selected tRNA genes is also seen under 
these conditions [38]. 
Here, we examined cell growth following a switch from glucose to glycerol-based 
medium and growth at 37 °C on C160 occupancy of tDNA. Transfer of wild type cells from 
glucose medium (YPD) to repressive conditions of YPGly decreased C160 occupancy of 
tDNA-Leu and tDNA-Phe by 81% and 91%, respectively, but during the same interval only 
about 60% of C160 was degraded (compare Fig. 5A and 5B). These estimates suggested that a 
substantial portion of the Pol III complex remained intact and was released from chromatin 
independently of C160 degradation. As determined by western blotting, incubation in YPGly 
decreased expression of other Pol III complex subunits, although to a lesser extent than for 
C160 (Fig. 5A). 
To determine whether dissociation of the polymerase from DNA leads to disassembly 
of the Pol III complex, we tested how the transfer of cells from glucose medium to medium 
with glycerol followed by 2 h incubation at 37 °C affected the association between Pol III 
components. Using a GFP-specific antibody, the entire complex was immuno-purified from 
cells expressing AC40-GFP and C160-HA, and the interactions between different Pol III 
9subunits were examined by co-immunoprecipitation (Fig. 6A). AC40 protein purified from 
YPD and YPGly cells together with co-purified proteins were subjected to quantitative 
western blot analysis. The association of AC40 with C82 was clearly enhanced, more than 
two-fold, by the change in media, but AC40-C160- and AC40-C53 associations were also 
increased in YPGly cells (Fig. 6A). Moreover, immuno-purification of C160-HA, followed by 
western blotting also showed an increase in co-immunoprecipitated subunits C82, C53 and 
AC40 (Fig. 6B).Theses results indicate that Pol III release from chromatin is not related to Pol 
III complex dissociation, but that interactions between subunits may be even strengthened. 
Discussion
In this work we present evidence that inhibition of Pol III transcription in yeast is 
correlated with degradation of the Pol III catalytic subunit C160. Furthermore, we showed for 
the first time that C160 is ubiquitylated and degraded by proteasomes. C160 degradation 
during stress caused by transfer to media that promotes fermentation from media that favors 
respiration is preceded by Pol III release from chromatin. Although the steady-state levels of 
other Pol III subunits also decreased, the strength of the Pol III complex association increased 
in repression conditions. 
We sought to address whether, similar to the largest Pol I and Pol II subunits, Pol III 
regulation involves controlled degradation of the largest subunit of the complex, C160, under 
conditions that repress Pol III activity. To do this, we examined the kinetics of decreases in 
steady-state levels of the C160 protein in cells treated with rapamycin, 6-AU or MPA or 
transferred to medium having a non-fermentable carbon source. The half-life of the C160 
protein, determined in the CHX chase experiment, was about 120 min (Fig. 1) and under 
stress the C160 levels were reduced by half faster, even when de novo synthesis was not 
blocked by CHX (Fig. 2).
Our results strongly support the hypothesis that decreased amounts of C160 arise from 
protein degradation. First, the effect of rapamycin on C160 expression was nearly identical to 
that seen for Rpb1, which, in response to rapamycin treatment, is degraded in the chromatin-
bound state [16]. The mechanism of C160 degradation in rapamycin-treated cells could be 
analogous because it is also dependent on the peptidyl prolyl isomerase Rrd1 (Fig. 2). Second, 
GTP depletion only slightly reduces Pol II-dependent mRNA synthesis except for some 
transcripts involved in nucleotide biosynthesis that show specific up-regulation [35,36]. 
Finally, down-regulation of C160 upon transfer of yeast to a non-fermentable carbon source is 
dependent on proteasome activity, demonstrating that C160 is primarily degraded by the 
proteasome. Based on our findings we conclude that Pol III inhibition activates degradation of 
its largest subunit, C160. Interestingly, recently reported data showing destabilization of Pol I 
machinery in human cells treated with the DNA intercalator BMH-21 support the possibility 
that inhibition of Pol I activity drives degradation of its largest subunit [44]. 
Pol II and Pol I are degraded by different mechanisms depending on the type of stress, 
which may also affect Pol III degradation. Our study focused on C160 degradation and Pol III 
repression in response to growth on a non-fermentable carbon source. In the natural 
environment, yeast responds to variations glucose availability by undergoing frequent 
physiological transitions between fermentation and respiratory growth using non-fermentable 
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carbon sources. Yeast must also adapt to temperature variations. Here we induced similar 
metabolic changes by transferring yeast from a glucose-rich medium to a non-fermentable 
glycerol medium at elevated temperature to monitor C160 expression in the context of Pol III 
association with chromatin and stability of the Pol III complex.
Our data support and expand the basis for the coupling of carbon metabolism to Pol III 
transcription. We showed that the catalytic Pol III subunit C160 undergoes proteasomal 
degradation in response to a shift from a glucose to a glycerol carbon source. Moreover, we 
detected ubiquitylated C160. Together these findings strongly support a role for ubiquitylation 
in proteasome-mediated Pol III degradation. Future studies will be needed to define the 
mechanism that mediates this ubiquitylation, although these findings indicate that Pol III 
degradation occurs independently of the ubiquitin ligase Rsp5, suggesting that the mechanism 
differs from that described for Pol II inhibition following DNA damage [8]. 
We have shown that most Pol III complexes are released from chromatin upon shifting the 
cells to a non-fermentable carbon source (Fig. 5B). This finding is consistent with our 
previous work showing a significant decrease in Pol III transcription under similar conditions 
[37,38]. The relatively smaller decrease in the amount of C160 indicates that designation of 
C160 for degradation does not necessarily correspond with Pol III complex removal from 
DNA under repression induced by a non-fermentable carbon source. In contrast, degradation 
of the yeast Pol II subunit Rpb1 in response to unsuccessful resolution of Pol II blockage at 
DNA lesions is a rationale for removal of Pol II from DNA and is required for cell survival 
[8].
C160 is present in excess relative to other Pol III subunits [45], which may be because, as the 
largest core subunit, C160 serves as a scaffold for Pol III assembly. Under stress conditions, 
this excess may be unnecessary and thus C160 is degraded. Indeed, general responses to stress 
often induce proteolysis of unneeded proteins that may be harmful to the cell [46].
Another observation is enhanced interactions between Pol III subunits under repression 
conditions promoted release of the Pol III complex from chromatin (Fig. 6). Degradation of 
excess C160 may serve to prevent de novo assembly of the Pol III complex under repression 
conditions but allow recruitment of existing complexes when environmental conditions are 
favorable for transcription. Overall, these findings suggest that repression of Pol III 
transcription is associated with Pol III assembly. 
CONCLUSIONS
 Repression of RNA polymerase III is correlated with degradation of its subunit, C160
 C160 protein is ubiquitylated and degraded in proteasome
 Interaction between RNA polymerase III subunits is enhanced under repression
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FIGURE 1. (A) The largest protein subunit of Pol III, C160, has limited stability. A yeast 
strain expressing C160 fused to an HA tag was grown in rich glucose medium until the 
exponential growth phase was reached and cycloheximide (CHX) was added to a final 
concentration 100 µg/ml and growth was allowed to proceed at 30 C. The cells were then 
harvested as indicated and examined by western blotting using anti-HA antibody and 
antibodies specific for selected Pol III subunits and Maf1. Actin was used as a loading 
control. (B). Stability of C160 is decreased in a mutant yeast strain with low Pol III activity. 
Control (wt) and isogenic rpc128-1007 cells encoding C160 fused to the TAP epitope were 
treated with CHX as described above. C160 stability was monitored by western blotting using 
peroxidase anti-peroxidase (PAP) antibody. C160-TAP levels were normalized to the loading 
control (Pgk1) and calculated relative to the amount in untreated wild type yeast that was set 
to 1. Band intensities from western blot images were quantified using MultiGauge v3.0 
software (Fujifilm). Bars represent the mean ± standard deviation of three independent 
experiments. ** and * asterisks indicate, respectively, p value < 0.005 and < 0.05.
FIGURE 2. Reduced levels of C160 protein under conditions that lead to global repression of 
Pol III-mediated transcription. Strains encoding C160 with an HA epitope were grown in rich 
glucose medium (YPD) (A and C) or in minimal medium without uracil (B) to the exponential 
growth phase and then subjected to stress conditions before harvest at the indicated time 
points: (A) Control (wt) and isogenic rrd1Δ cells incubated with 200 ng/ml rapamycin (RAP) 
at 30 C. (B) Cells incubated with 100 µg/ml 6-AU or 100 µg/ml MPA at 30 C; (C) Cells 
transferred to rich glycerol medium (YPGly) and incubated at 37 C. C160 levels were 
monitored by western blotting with anti-HA antibody and quantified as described in Figure 1. 
Vma2, Pgk1 or actin were used as loading controls. Bars represent the mean ± standard 
deviation of three independent experiments. ** and * asterisks indicate, respectively, p value 
< 0.001 and < 0.05.
FIGURE 3. Identification of C160-ubiquitin conjugates. (A) Yeast expressing C160 with HA 
epitope were grown in rich glucose medium at 30 C to exponential growth phase (YPD), 
transferred to rich glycerol medium (YPGly), incubated 30 min at 37 C and harvested. 
Immunoprecipitation of C160 was monitored by western blotting with anti-HA antibody (α-
HA). TOT, 2% of total protein extracts; FT, protein unbound to α-HA, IP- α-HA protein, 
bound to α-HA. The middle lane was loaded with a molecular weight marker indicating the 
position of the 170 kDa protein. The dashed line indicates where the image was cropped to 
remove irrelevant lanes. (B) Yeast expressing TAP-tagged C160 and His-tagged ubiquitin, 
grown on minimal medium without tryptophan, were subjected to double immuno-
purification. C160-TAP bound by IgG Sepharose resin (S-beads) was eluted and incubated 
with nickel resin (Ni-beads). Respective fractions were analyzed by western blotting with 
TAP- or ubiquitin (Ub)-specific antibodies. The same experiment was performed with a yeast 
strain encoding untagged C160. 
FIGURE 4. Proteasome-mediated C160 degradation. Wild type strain, snq2Δpdr5Δ and 
ump1Δ mutants (A) or rsp5 alleles (B), all expressing C160-HA, were grown in rich glucose 
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medium (YPD) at the indicated temperatures ((A, left panel with snq2Δpdr5Δ strain) 30 °C 
(A, right panel with ump1Δ strain and B) 23 °C), transferred to rich glycerol medium (YPGly) 
and incubated at 37 °C for 2 h. Upon transfer to YPGly, snq2Δpdr5Δ cells were additionally 
treated with either DMSO or MG132. Cell lysates were analyzed by western blotting. Vma2 
or actin were used as a loading controls. The amounts of C160 protein expressed were 
quantified as described for Figure 1. 
FIGURE 5. Pol III is affected by a switch from fermentation to aerobic respiration. Strain 
expressing C160-HA and control untagged strain grown in glucose medium were harvested in 
the exponential phase (YPD) or transferred to glycerol medium and cultivated in YPGly for 2 
h at 37 °C. (A) Levels of Pol III subunits were examined by western blotting and quantified as 
described for Figure 1. Pgk1 was used as the loading control. (B) C160 occupancy on tDNA 
was determined by ChIP. Cross-linked chromatin was immunoprecipitated with antibodies 
against HA followed by quantitative real-time PCR with primers specific to single tDNA 
genes: tL(CAA)G1 and tF(GAA)H1 (designated as tDNA-Leu and tDNA-Phe) The 
occupancy of C160-HA is represented relative to the level of C160-HA in the wild type strain 
grown on glucose, which was set to 1. Bars represent the mean ± standard deviation of three 
independent experiments.
FIGURE 6. Effect of switch of yeast between fermentation and aerobic respiration on 
interactions between Pol III subunits. Extracts were prepared from cells encoding AC40-GFP 
and C160-HA (A) or C160-HA (B). Pol III was immunoprecipitated from yeast extracts by 
GFP-specific (A) or HA-specific antibody (B). AC40 (A) or C160 (B) immune-purified from 
equal amounts of YPD and YPGly cells were examined by western blotting together with co-
purified proteins with antibodies specific for HA, C82, C53 or AC40. The ratio of co-purified 
and input proteins was calculated. Bars represent the mean ± standard deviation of three 
independent experiments.
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FIGURE S1. Transition of yeast from fermentative to glycerol medium caused down-regulation 
of C160-HA or C160-TAP in strains having various genetic backgrounds. Derivatives of 
YPH499 encoding C160 with TAP epitope (A) or MB159-4D encoding C160 with HA (B) or 
TAP epitope (C) were grown in rich glucose medium (YPD) to exponential growth phase, 
transferred to rich glycerol medium (YPGly), incubated at 37 C and harvested at the indicated 
time points. C160 levels were monitored by western blotting with anti-HA antibody or 
peroxidase anti-peroxidase (PAP) antibody. Actin was used as a loading control.
Supplementary Table 1. The yeast strains used in this study.
Strain Genotype
Source of 
reference Figure
YPH499 MATa ade2-101 lys2-801 leu2-Δ1 his3-Δ200 ura3-52 trp1-Δ63 [1]  
MB159-4D MATa SUP11 ade2-1 lys2-1 leu2-3,112 his3 ura3-1 [2]  
MJ15-9C MATa SUP11 ade2-1 lys2-1 leu2-3,112 his3 ura3-1 rpc128-1007 [2]  
MW4415 MATa ade2-101 lys2-801 leu2-Δ1 his3-Δ200 ura3-52 trp1-Δ63 RPC160::3HA::KanMX6 [3]
1A, 2B, 2C, 
3A, 4A, 
4B, 5A, 5B, 
6B
YPH499 
C160-TAP
MATa ade2-101 lys2-801 leu2-Δ1 his3-Δ200 ura3-52 
trp1-Δ63 RPC160::TAP-K.l. URA3 This study 3B, S1A
MB159-4D 
C160-HA
MATa SUP11 ade2-1 lys2-1 leu2-3,112 his3 ura3-1 
RPC160::3HA::KanMX6 [4] S1B
MB159-4D 
C160-TAP
MATa SUP11 ade2-1 lys2-1 leu2-3,112 his3 ura3-1 
RPC160::TAP-K.l. URA3 This study 1B, S1C
MJ15-9C 
C160-TAP
MATa SUP11 ade2-1 lys2-1 leu2-3,112 his3 ura3-1 
rpc128-1007 RPC160::TAP-K.l. URA3 This study 1B
W303-1A MATa ade2-1  his3-11,15 leu2-3,112 trp1-1 ura3-1 can1-100 [5]  
W303 C160-
HA
MATa ade2-1  his3-11,15 leu2-3,112 trp1-1 ura3-1 
can1-100  RPC160::3HA::KanMX This study 2A
FA212/10-2D MATα ade2-1  his3-11,15 leu2-3,112 trp1-1 can1-100 rrd1Δ::KanMX [6]  
EM4-3C MATα ade2-1  his3-11,15 leu2-3,112 trp1-1 ura3-1 can1-100 RPC160::3HA::KanMX rrd1Δ::KanMX
This study, 
genetic cross 
of W303 
C160-HA and 
FA212/10-2D
2A
YAS6 MATα can1-100 ade2-1 lys2-1 ura3-52 leu2-3,112 his3-Δ200 trp1-Δ900 GAL+ RAD5 ump1Δ::TRP1 [7]  
YPH499 
C160-HA 
ump1Δ
MATa ade2-101 lys2-801 leu2-Δ1 his3-Δ200 ura3-52 
trp1-Δ63 RPC160::3HA::KanMX6 ump1Δ::TRP1 This study 4A
YYM4
MATa ura3 his3 leu2 trp1 lys2 ade2 pdr5Δ::TRP1 
snq2Δ::hisG [8]  
YYM4 C160-
HA
MATa ura3 his3 leu2 trp1 lys2 ade2 pdr5Δ::TRP1 
snq2Δ::hisG RPC160::3HA::KanMX6 This study 4A
PC10 MATα  his3Δ-200 leu2-3, 112 ura3-52 lys2-801 trp1-1 rsp5-1 [9]  
PC7 MATα  his3Δ-200 leu2-3, 112 ura3-52 lys2-801 trp1-1 rsp5-19 [10]  
PC10 C160-
HA
MATα  his3Δ-200 leu2-3, 112 ura3-52 lys2-801 trp1-1 
rsp5-1 RPC160::3HA::KanMX6 This study 4B
PC7 C160-
HA
MATα  his3Δ-200 leu2-3, 112 ura3-52 lys2-801 trp1-1 
rsp5-19 RPC160::3HA::KanMX6 This study 4B
AC40-GFP MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 RPC40::GFP [11]  
AC40-GFP 
C160-HA
MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 RPC40::GFP 
RPC160::3HA::KanMX6 This study 6A
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